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Abstract
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the develop-
ment of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper 
molecular knowledge; so, more options can be offered to patients with driver mutations. Groups with specific treatments 
account for around 25% and demonstrate significant increases in overall survival, and in some subgroups, it is important 
to evaluate each treatment alternative in accordance with scientific evidence, and even more so with immunotherapy. New 
treatments similarly mean that we must reconsider what should be done in oligometastatic disease where local treatment 
attains greater value.
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Methodology
Relevant studies published in peer review journals were used 
for the guideline elaboration. The Infectious Diseases Society 
of America grading system was used to assign levels of evi-
dence and grades of recommendation.
Diagnosis
Diagnosis: pathology and molecular testing
The pathological diagnosis of non-small cell lung cancer 
(NSCLC) should be made according to the World Health 
Organization (WHO) classification [1]. The International 
Association for the Study of Lung Cancer (IASLC) provided 
adenocarcinoma classification as well as key recommenda-
tions for the management of small biopsies and cytology [2]. 
For therapeutic implications, specific subtyping of NSCLC is 
strongly recommended whenever possible. Limited diagnostic 
workup is also recommended to preserve as much tissue as 
possible for further molecular assessments.
The Spanish Society of Medical Oncology and the Spanish 
Society of Pathology published evidence-based recommenda-
tions for molecular testing in lung cancer [3]. Genetic profiling 
of NSCLC advanced disease is recommended in daily clinical 
practice by both ESMO [4] and ASCO [5] guidelines, as it has 
demonstrated to have an impact on patients’ outcomes (I,A). 
New molecular guidelines recommend to include upfront 
ROS-1 testing along with EGFR and ALK in stage IV non-
SCC and endorse to include other additional genes such as 
BRAF, MET, HER2, KRAS and RET for laboratories that 
perform next-generation sequencing (NGS) testing [5]. Immu-
nohistochemistry can be considered as an alternative to fluo-
rescence in situ hybridization for ALK and/or ROS1 testing.
In EGFR mutant patients progressing on first- or second-
generation EGFR TKI, the detection of EGFR T790M second-
ary resistance mutations in tumor tissue is recommended (I,A). 
Liquid biopsies or molecular DNA profiling in blood (ctDNA) 
is currently accepted as a good surrogate for EGFR testing in 
tissue (II,A), enabling clinicians to collect samples in a non-
invasive approach [6, 7].
All patients with advanced NSCLC should, at baseline, 
have their tissue assessed for programmed cell death 1 ligand 
(PD-L1) expression by IHC test for selecting patients for anti-
programmed death 1 (PD-1) or anti-PD-L1 treatment [8].
Disease staging
In NSCLC, the following staging work-up is highly 
recommended:
• Clinical history, including smoking and family his-
tory; physical examination, performance status (PS) 
and weight loss should be assessed.
• Blood test, including hematology, renal and hepatic 
function.
• Bronchoscopy.
• Chest and upper abdomen (including liver and adrenal 
glands) computerized tomography (CT).
• Brain CT or magnetic resonance imaging (MRI) is rec-
ommended for patients undergoing radical treatment, 
in patients with EGFR mutation or ALK translocation 
or if there are neurological symptoms in the physical 
examination.
• Bone scan is recommended if there is bone pain, high 
serum calcium or high alkaline phosphatase.
  In patients undergoing potentially radical treatment, 
additional recommendations should be considered:
• Whole-body FDG-positron emission tomography 
(PET–CT).
• Pulmonary function tests.
• Ergospirometry if the pulmonary function tests are not 
normal.
• Chest MRI in Pancoast tumour.
• Invasive mediastinal staging, endobronchial ultra-
sound-guided fine-needle aspiration and/or endo-
scopic ultrasound-guided fine-needle aspiration are 
recommended in patients with suspected mediastinal or 
hilar lymph nodes (LNs) in the PET–CT. For patients 
with suspected LNs on PET–CT and negative EBUS/
EUS results, an additional mediastinoscopy is recom-
mended. In patients with no suspected LN on the PET-
CT, invasive mediastinal staging is also recommended 
in patients with enlarged mediastinal LNs (≥ 1.5 cm), 
in tumors ≥ 3 cm and/or in patients with central tumors.
• Histological and cytological confirmation is strongly 
recommended in the presence of pleural/pericardial 
effusion or isolated metastatic site.
Staging system
During the 16th World Congress of Lung Cancer, the 
International Association for the Study of Lung Cancer 
(IASLC) proposed the TNM 8th edition that was accepted 
by the Union for International Cancer Control (UICC) and 
the American Joint Committee on Cancer (AJCC) [9]. The 
TNM 8th edition is effective since January 2017 (Table 1). 
The most striking changes in the TNM 8th edition are the 
further subdividing and detailing of both T and M stages, 
although the consequences for therapeutic approach are 
not yet obvious in all situations.
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Stage I–II
A multidisciplinary tumor board evaluation of NSCLC 
patients with stage I-II disease is strongly recommended, 
even non-surgical patients. It has to include a preoperative 
cardiopulmonary assessment.
Surgery
For stage I–II NSCLC patients and no medical contraindi-
cations to surgery, surgical resection remains the treatment 
of choice, yielding the best potential choice of cure for 
these patients (IB).
The type of surgery resection depends on the extension 
of the disease, the location of the tumor and the preopera-
tive evaluation:
• In stage I–II medically fit NSCLC patients, lobectomy 
or anatomic pulmonary resection is recommended 
rather than sublobar resection (I,B). Systematic medi-
astinal lymph node dissection is recommended over 
selective sampling lymph node dissection for accu-
rate pathologic staging [10] (IB). For stage II patients 
undergoing anatomic resection, mediastinal lymph 
node dissection may provide additional survival benefit 
over sampling [11] (II,B).
• A sublobar resection (anatomical segmentectomy) is 
recommended over nonsurgical therapy for patients 
who cannot tolerate a lobar resection due to decreased 
pulmonary function or comorbid disease (I,B).
• For patients with a stage I predominantly ground glass 
opacity with lesion ≤ 1 cm, sublobar resection with nega-
tive margins is suggested over lobectomy (I,B).
• Reresection is recommended for patients with positive 
margins in resected stage I–II NSCLC patients. If it is not 
possible, postoperative radiotherapy may be considered 
[12].
Adjuvant therapy
Overall survival (OS) benefit of adjuvant treatment is limited 
to cisplatin-based chemotherapy in completely resected fit 
stage II–III patients [13].
• Four cycles of cisplatin-based chemotherapy following 
complete resection in stage II NSCLC patients remain 
the standard of care in adjuvant setting, offering a 5% OS 
benefit [13] (I,A).
• Stage I (7th TNM edition) NSCLC patients do not ben-
efit from adjuvant therapy except those patients with 
tumors > 4 cm [5, 14] (I,C).
• In elderly fit patients, adjuvant platinum-based chemo-
therapy should be considered.
• Postoperative radiotherapy (PORT) is not indicated in 
completely resected stage I–II NSCLC patients [15] (I,A-
II,A).
Neoadjuvant therapy
Preoperative chemotherapy has the potential role to reduce 
tumor size, increase operability, and eliminate micrometas-
tases. A meta-analysis with 15 randomized trials showed 
a significant benefit of preoperative chemotherapy on OS 
(representing an absolute survival improvement of 5% at 
5 years [16]. Although neoadjuvant chemotherapy has simi-
lar impact on OS than adjuvant chemotherapy, more conclu-
sive evidence favors adjuvant treatment (I,B).
Stereotactic ablative radiotherapy (SART)
SART is recommended for medically inoperable NSCLC 
patients with node negative tumors ≤5 cm (2C). Several non-
randomized studies suggest that SART might be a suitable 
option for operable patients older than 75 years [17] (II,C).
Other adjuvant treatments
Adjuvant EGFR TKI in patients with EGFR mutation has 
not demonstrated a survival benefit yet. Several trials in 
patients with EGFR mutations or ALK translocations in 
adjuvant setting are ongoing [18].
Table 1  TNM classification 8th edition
Stage T N M
Occult TX N0 M0
0 Tis N0 M0
IA1 T1a(mi)/T1a N0 M0
IA2 T1b N0 M0
IA3 T1c N0 M0
IB T2a N0 M0
IIA T2b N0 M0
IIB T1a-T2b N1 M0
T3 N0 M0
IIIA T1a-T2b N2 M0
T3 N1 M0
T4 N0/N1 M0
IIIB T1a-T2b N3 M0
T3/T4 N2 M0
IIIC T3/T4 N3 M0
IVA Any T Any N M1a/M1b
IVB Any T Any N M1c
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Stage III
Stage III NSCLC is a heterogeneous and complex disease 
that has been classified into different subgroups: resectable, 
potentially resectable and unresectable locally advanced 
NSCLC. Treatment decision should be taken by an experi-
enced multidisciplinary team (Fig. 1).
Resectable and potentially resectable NSCLC
• In patients with R0 resected stage III NSCLC, 4 cycles of 
adjuvant platinum-based chemotherapy should be given 
(preferably cisplatin doublet) [19] (I,A).
• In patients with pathological N2 NSCLC, PORT appears 
to improve OS in non-randomized analysis, and it is usu-
ally administered after adjuvant chemotherapy (II,A).
• In patients with potentially resectable disease, the opti-
mal treatment strategy remains unclear. Several phase 
III trials and a meta-analysis showed that induction ther-
apy followed by surgery might be better than surgery 
alone [20]. Surgery has been compared to radiotherapy 
in patients with tumor response after induction chemo-
therapy, without differences in overall survival [21]. Sur-
gery was also compared to radiotherapy after induction 
chemoradiotherapy in the Lung Intergroup Trial 0139 
showing better progression-free survival in the surgery 
arm, with no differences in OS except in the unplanned 
analysis in the subset of patients who underwent lobec-
tomy [22]. The optimal chemotherapy regimen has not 
been established in randomized trials, although cisplatin-
based chemotherapy is recommended.
• In case of superior sulcus (Pancoast) tumors, concur-
rent chemoradiation followed by surgery is the preferred 
option [23] (Table 2).
Unresectable NSCLC
Unresectable LA-NSCLC includes stage IIIA N2 (bulky 
and/or multiple nodal involvement), stage IIIB and IIIC.
• Concurrent chemoradiotherapy is the treatment of choice 
for medically fit patients (I,A). Several randomized clini-
cal trials and a meta-analysis have shown a higher 5-year 
survival rates favoring this strategy over sequential 
approaches [24].
• Cisplatin-based combinations are recommended for med-
ically fit patients (usually with etoposide or vinorelbine) 
[24].
• Radiotherapy is usually given at a dose of 60–66 Gy in 
30–33 fractions over 6–7 weeks. Higher doses are not 
recommended outside of clinical trials [25].
• If concurrent chemoradiotherapy is not feasible due to 
poor performance status, comorbidities, and/or unfit 
patients, a sequential approach is a reasonable option 
[26].
• There is no role for prophylactic cranial irradiation in 
stage III (II,A).
• In patients with no progressive disease after concurrent 
chemoradiotherapy, consolidation treatment with Dur-
valumab for 1 year has shown to improve progression-
free survival (PFS) and OS (I,A) [27–29]. The European 
Medical Agency has recently approved consolida-
tion with Durvalumab in patients with PD-L1 expres-
sion ≥ 1% based on an unplanned post hoc analysis.
Fig. 1  Treatment algorithm for 
Stage III
Treatment Algorithm for Stage III
Potenally Resectable
Stage III:
T1-3 N2
T4 N0-1
Unresectable Stage III
R0 resected Stage III Adjuvant Planum based
CT+/-PORT (I,A-II,A)
CT or CT/RT followed by
surgery (I,A)
Definive CT/RT (I,A)
PS2, and/or comorbidity
and/or impaired lung
funcon
PS 0-1, no comorbidity,
good pulmonary funcon
Concurrent
CT/RT (I,A)
Sequenal
CT/RT (I,A)
Durvalumab
(I,A)
No PD
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Table 2  Summary of recommendations
Diagnosis WHO classification for pathological diagnosis is required and also 
IASLC classification of adenocarcinoma
For therapeutic implications, specific subtyping of NSCLC is strongly 
recommended
Molecular testing in stage IV non-SCC should include EGFR muta-
tions, ALK and ROS-1 translocations by a validated technique
In patients progressing to first or second generation EGFR TKI determi-
nation of EGFR T790M in plasma or tissue should be performed
PD-L1 expression should be test to all patients with advanced NSCLC 
at baseline
Staging Comprehensive evaluation must include thorax and upper abdomen CT
More extensive evaluations are recommended if a radical approach is 
considered
Stage disease must be classified using the TNM 8th edition
Stage I–II Patients should be evaluated in a multidisciplinary tumor board
 Medically fit for surgery Lobectomy or anatomic pulmonary resection plus systematic mediasti-
nal lymph node dissection
 Medically inoperable, node negative NSCLC tumours ≤ 5 cm SART 
 Adjuvant chemotherapy (four cycles of cisplatin-based chemo-
therapy)
Recommended in stage II
Not recommended in stage I 7th TNM edition (except T > 4 cm)
 Post operative radiotherapy (PORT) Not indicated in completely resected stage I–II
Stage III Treatment decision should be taken by an experienced multidisciplinary 
team
 Completely resected Adjuvant chemotherapy (four cycles of adjuvant cisplatin-based chemo-
therapy) ± PORT
 Potentially resectable Resection followed by adjuvant chemotherapy
Induction chemotherapy or chemoradiotherapy followed by surgery
 Unresectable stage III Medically fit: concurrent chemoradiotherapy with cisplatin-based 
chemotherapy
Sequential chemoradiotherapy if concurrent treatment is not feasible
PCI is not indicated
Durvalumab if no progressive disease after concurrent chemoradio-
therapy
Stage IV
Stage IV without driver mutations
Fist line
 PD-L1 ≥ 50% Pembrolizumab
Note: Combination of immunotherapy plus standard chemotherapy may 
be considered
 PD-L1 < 50% or unknown Platinum-based chemotherapy based on tumor histology:
Squamous cell carcinoma (SCC) Platinum-based doublets (4, up to 6 cycles)
Immunotherapy (atezolizumab or pembrolizumab) and carboplatin plus 
paclitaxel or nab-placlitaxel)(#)
Non-squamous-cell carcinoma (non-SCC) Platinum-based doublet:
Cisplatin/pemetrexed has more efficacy and less toxicity than cisplatin/
gemcitabine
Bevacizumab added to a platinum doublet. if there are no contraindica-
tions
Pemetrexed maintenance
Immunotherapy  (atezolizumab(#) or pembrolizumab) plus standard 
chemotherapy
Elderly Comprehensive geriatric assessment is highly recommended
 Fit patients Decision according to histology and PD-L1 expression levels
 Unfit or comorbidities Single agent chemotherapy
PS 2 Combination therapy
Single-agent therapy
Best supportive care
PS 3–4 Best supportive care
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Stage IV
Stage IV without driver mutations (Fig. 2)
First‑line therapy
• For stage IV, PS 0–1 NSCLC patients without driver 
mutations whose tumors express PD-L1 at levels of 50% 
or greater (tumor proportion score (TPS) ≥ 50%), pem-
brolizumab is recommended in the absence of contrain-
dications to use immunotherapy [30] (I,A).
• For patients with low (TPS < 50%) or unknown PD-L1 
expression, chemotherapy with platinum doublets should 
be considered in all stage IV PS 0–1 NSCLCs without 
driver mutations (I,A). Data have shown that platinum 
combination therapy increases OS and improves quality 
Table 2  (continued)
Second line
PS 0–2
 If no prior immunotherapy Pembrolizumab (PD-L1 ≥ 1%), nivolumab or atezolizumab
 If prior immunotherapy Platinum doublets
 If contraindication for immunotherapy Docetaxel–nintedanib (non-SCC)
Docetaxel (SCC, non-SCC)
Pemetrexed (non-SCC)
 If prior immunotherapy alone Platinum doublets
 If prior immunotherapy + CT Docetaxel–nintedanib (non-SCC)
Docetaxel (SCC, non-SCC)
Pemetrexed (non-SCC)
PS 3–4 Best supportive care
Stage IV with driver mutations
EGFR mutation
First-line EGFR TKI Erlotinib, gefitinib, afatinib,  dacomitinib(#), osimertinib
 Brain metastasis Osimertinib
After EGFR TKI progression
 Clinical benefit maintained or oligoprogressive disease Continuation with the EGFR TKI
 T790 M positive Osimertinib (if not previously given)
 T790 M negative Platinum-based chemotherapy
ALK mutation
First-line ALK TKI Alectinib,  brigatinib(#), crizotinib or ceritinib
Progression to crizotinib Ceritinib, alectinib or  brigatinib(#)
 Brain metastasis Alectinib,  brigatinib(#) or  lorlatinib(#)
Other genetic alterations
ROS-1 Crizotinib
B-RAFv600 Dabrafenib plus trametinib
Oligometastatic disease
Systemic therapy and local ablative strategies
Local ablative strategies and TKI-continuation if clinical benefit is still 
retained (if actionable mutation)
Follow-up
Smoking cessation counseling
Curative intent
 Surgery Medical history, physical examination and spiral chest CT scan every 
6–12 months for 2 years and annually thereafter
 SART Medical history, physical examination and spiral chest CT scan every 
6 months for 3 years and annually thereafter
PET–CT ± biopsy if recurrence is suspected
Advanced disease
Early palliative care
Evaluation of response every 6–12 weeks
(#) Not EMA approved
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of life (QoL) compared to supportive care, single-agent 
cisplatin or other monotherapy [31–34].
• Meta-analyses have shown higher response rates (RRs) 
and a slightly longer OS for cisplatin combinations than 
for carboplatin combinations [35] (I,B). Carboplatin can 
be recommended if any contraindication for cisplatin 
exists.
• Non-platinum regimens have reported lower efficacy than 
platinum regimens [36] (I,A).
• Recently, results from several phase III trials have shown 
a significant benefit in terms of efficacy for the addition 
of immunotherapy to platinum-based chemotherapy 
regardless of the PD-L1 status [37–41] (I,A-I,B).
• Cisplatin-based combinations and some modalities of 
treatment will be selected based on tumor histology:
For squamous cell lung cancer (SCC) 
• For PS 0–1 SCC patients, without major comorbidities 
and with low (TPS < 50%) or unknown PD-L1, platinum-
based doublets with the addition of a third-generation 
cytotoxic agent (gemcitabine, vinorelbine, taxanes) are 
recommended (I,A). The different combinations have 
shown comparable efficacy [42].
• Four cycles are recommended, up to a maximum of six 
cycles in selected cases [43, 44] (I,A).
• The expected toxicity profile should contribute to the 
selection of the chemotherapy regimen. The nab-pacli-
taxel/carboplatin regimen has shown in a phase III trial 
to have higher RRs (with a larger impact in SCC) than 
paclitaxel/carboplatin and less neurotoxicity (I,B) [45].
• Recently, two randomized phase III trials have shown that 
the addition of immunotherapy (atezolizumab or pem-
brolizumab) to standard first-line chemotherapy (carbo-
platin plus paclitaxel or nab-placlitaxel) in SCC, results 
in significantly longer PFS with atezolizumab (I,B) [38] 
and OS and PFS with pembrolizumab (I,A) [40] than 
chemotherapy alone, regardless of PD-L1 expression. It 
is important to underline that these combinations were 
not approved by the European Medical Agency when this 
guideline was submitted.
For non‑squamous cell lung cancer (Non‑SCC) 
• Any platinum-based doublets with a third-genera-
tion agent can be used in non-SCC patients with low 
(TPS < 50%) or unknown PD-L1 [42] (I,A).
• Pemetrexed-based combination chemotherapy represents 
a therapeutic option. This regimen showed a slight but 
significant survival benefit compared with gemcitabine 
or docetaxel-based combinations (results coming from a 
Stage IV NSCLC (no targetable alteraons)
PS 0-1 PS 2 PS 3-4
1st
line
2nd
line
3rd
line
PD-L1< 50%
PD-L1≥ 50%
SCC and non-SCC
Pembrolizumab (I,A)(*)
Planum based-CT
CT, chemotherapy; SCC, squamous; BSC, best supporve care
(*) combinaon of immunotherapy + CT may be considered#
# Not EMA approved
Docetaxel + Nintedanib (non-SCC)
Pemetrexed (non-SCC)
Docetaxel
non-SCC
Planum+Pemetrexed (II,A)
Taxol+CBDCA+Bevacizumab (I,A)
Paclitaxel+CBDCA+Bev+Atezolizumab# (I,A)
Planum+Pemetrexed+Pembrolizumab(I,A)
Planum+Pemetrexed+Atezolizumab#(I,b)
If no prior IO:
• Nivolumab (IA)
• Atezolizumab (IA)
• Pembrolizumab (PD-L1 + >1%) (IA)
Docetaxel (IB)+/- Nintedanib (II,B)
Pemetrexed(I,B) (if not previously given)
Docetaxel +/- Nintedanib
Pemetrexed (if not previously given)
If no prior IO:
• Nivolumab (IA)
• Atezolizumab (IA)
• Pembrolizumab (PD-L1 + >1%) (IA)
Docetaxel (IB)
Planum based-CT (I,A)
Planum+Taxane+Pembrolizumab#(I,A)
Planum+Taxane+Atezolizumab#(I,B)
Docetaxel (if not previously given)
SCC
Single agent CT (I,B)
Carboplan-based
CT (II,A)
BSC (II,B)
Fig. 2  Treatment algorithm for Stage IV with no targetable alterations
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meta-analysis and a preplanned subgroup analysis of a 
randomized phase III trial) [46, 47] (II,A).
• Bevacizumab/paclitaxel/carboplatin combination chem-
otherapy followed by maintenance bevacizumab has 
shown improvement in OS in two randomized clinical 
trials and, therefore, it can be offered to patients with 
advanced PS 0–1 non-SCC and no contraindications for 
antiangiogenic treatment [6, 48] (I,A).
• Maintenance therapy can be considered in those PS 0–1 
patients with at least stable disease and who have recov-
ered from residual toxicity after first-line chemotherapy:
• Pemetrexed switch maintenance could be considered 
after four cycles of non-pemetrexed platinum-based 
chemotherapy [49] (I,B).
• Pemetrexed continuation maintenance should be con-
sidered in patients having disease control after four 
courses of pemetrexed platinum-based chemotherapy 
[50] (I,A).
• Recently, three randomized phase III trials have shown 
that the addition of immunotherapy (pembrolizumab or 
atezolizumab) to standard first-line chemotherapy (pem-
etrexed platinum-based combination or bevacizumab 
plus chemotherapy) in non-SCC resulted in significantly 
longer OS ± PFS than chemotherapy alone, regardless of 
PD-L1 expression [37, 39, 41]. It is important to under-
line that pembrolizumab with pemetrexed and platinum-
based chemotherapy was the only combination approved 
by the European Medical Agency when this guideline 
was submitted.
Second‑line therapy
Patients clinically or radiologically progressing after first-
line therapy, with a PS 0–1 and appropriate PS 2, should be 
offered second-line treatment (I,A). Second-line treatment 
should be individualized and treatment duration should be 
subject to tolerability and clinical benefit.
• In patients with metastatic non-SCC and SCC who have 
not received prior immunotherapy, and with no con-
traindications, single-agent pembrolizumab (PD-L1 
TPS ≥ 1%), nivolumab or atezolizumab is recommended 
(I,A). This recommendation is based on data from the 
main Phase III trials, showing significant improvements 
in OS and tolerability of immunotherapy agents when 
compared to single-agent docetaxel [51–54].
• Nintedanib added to docetaxel has demonstrated a sig-
nificant OS benefit as compared with docetaxel alone 
in previously treated stage IV, PS 0–1 adenocarcinoma, 
particularly in those patients progressing within 9 months 
after start of first-line therapy [55] (II,B).
• Docetaxel, or pemetrexed have demonstrated improve-
ment in terms of OS and QoL (I,B) and are recommended 
for those patients with contraindications to immunother-
apy or nintedanib combination therapy (non-SCC) [56, 
57].
• In patients who have received an immune checkpoint 
inhibitor as first-line therapy, platinum doublets are rec-
ommended (I,B).
• For those patients who have received first-line conven-
tional chemotherapyand immune therapy, single agent, 
docetaxel, pemetrexed (non-SCC) or docetaxel plus nin-
tedanib (non-SCC) could be considered (IIB).
• There is no sufficient evidence to recommend the use of 
cytotoxic drugs as fourth-line therapy or beyond; patients 
should be considered to be included in clinical trials, and 
continued best supportive care.
Elderly and PS2
Age should not be considered as a decisive factor for treat-
ment selection, and Comprehensive Geriatric Assessment 
would help to ascertain the true biological status [58].
• For those elderly fit patients with PS 0–1 and adequate 
organ function, first-line treatment decision should be 
based according to histology and PD-L1 expression lev-
els [59] (I,B). Single agent chemotherapy (vinorelbine, 
gemcitabine, docetaxel) is recommended for those with 
comorbidities or unfit patients [60] (IB).
• For patients with PS 2, chemotherapy prolongs OS 
compared to best supportive care (BSC) [61] (I,B). In 
an individualized-based decision, combination therapy, 
single-agent therapy, or palliative therapy alone may be 
used for PS 2 patients. In the first-line setting, platinum-
based doublets (preferably carboplatin) have superior 
efficacy to monotherapy, despite higher toxicity rates 
[62, 63] (II,A).
• Unfit patients with PS 3–4 should not receive active treat-
ment regardless of age because no benefit has been dem-
onstrated. Supportive care is recommended (II,B).
Stage IV with driver mutations (Fig. 3)
EGFR mutation
First‑line setting
• EGFR TKIs (gefitinib, erlotinib, afatinib) have shown 
superior PFS, RR, toxicity profile and QoL for EGFR 
TKIs as first-line treatment compared with platinum-
11Clinical and Translational Oncology (2019) 21:3–17 
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based doublets (I,A) [64, 65]. Only a prespecified suba-
nalysis showed a significant improvement in OS favoring 
afatinib in patients with Del19 mutations [65].
• Patients with PS 3–4 may also be offered an EGFR TKI, 
as they are likely to receive a similar clinical benefit to 
patients with good PS (III,A).
• Results from direct comparison of first-, second- and 
third-generation EGFR TKIs in previously untreated 
patients have been reported. Although a benefit in terms 
of PFS has been demonstrated for third-generation TKIs 
osimertinib (I,A) and dacomitinib (I,A) [66–68], to date 
only dacomitinib has shown a significant OS advantage 
(I,A) [69]. However, grade 3–4 treatment-related adverse 
events were significantly higher with dacomitinib. OS 
data from the FLAURA trial comparing osimertinib ver-
sus standard of care are still immature [67].
• An exploratory data on brain disease suggest that the 
probability of experiencing a progression on central 
nervous system (CNS) was lower with osimertinib and 
provided a higher intracranial activity (II,B) [70].
• Combinations of bevacizumab and erlotinib were also 
explored in the first-line setting demonstrating a sig-
nificant increase in PFS but only a slight trend of OS 
improvement with the combination [71–73] (I,B).
• Combination of pemetrexed-carboplatin and gefitinib has 
demonstrated a significant increase in PFS and OS in 
japanese population [74] (I,B).
After EGFR TKI progression
• Patients might benefit of continuation with the EGFR TKI, 
especially if clinical benefit is maintained from a sustained 
EGFR oncogenic blockade [7] or if there is an oligopro-
gressive disease treatable with local strategies (SART or 
surgery) (II,A) [75].
• EGFR Exon 20, T790 M mutation, is the main mecha-
nism of acquired resistance after first- or second-generation 
EGFR TKIs [76]. Osimertinib has demonstrated greater 
efficacy over platinum-based chemotherapy (I,A) [77].
• For patients with systemic symptomatic progression 
in whom T790 M cannot be detected or who have pro-
gressed to osimertinib, platinum-based chemotherapy 
remains the standard of care (II,A). The combination of 
atezolizumab plus bevacizumab plus chemotherapy has 
demonstrated a significant PFS benefit in the subgroup 
of patients with EGFR mutation (III,A) [50].
• Continuation of EGFR TKI with platinum-based chemo-
therapy does not impact on PFS nor on OS [78] (I,A).
ALK translocation
First‑line setting
• First-line treatment with ALK TKIs is the preferred 
treatment (I,A). Crizotinib and ceritinib have shown a 
  Stage IV NSCLC (known targetable drivers)
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Fig. 3  Treatment algorithm for Stage IV with known targetable drivers
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significant statistical improvement in terms of PFS and 
RR compared with chemotherapy in randomized phase 
III trials (I,A) [79, 80].
• Alectinib (I,A) and brigatinib (I,B) have shown a signifi-
cant improvement in PFS versus crizotinib and, therefore, 
are the preferred first-line options. Grade 3–5 adverse 
events were higher for patients treated with crizotinib 
[81, 82]. It is important to underline that brigatinib was 
not approved by the European Medical Agency when this 
guideline was submitted.
• Chemotherapy is indicated (III,B) in patients whose ALK 
results are not available and urgent systemic treatment 
is required. Treatment plan should be reassured when 
genotypic results were available.
• For patients who received chemotherapy in the first-line, 
crizotinib should be recommended as second-line treat-
ment (I,A) [83]. Alectinib and ceritinib should also be 
considered, although no specific trials have been con-
ducted.
After ALK TKI progression
• For patients who develop resistance or are intolerant 
to crizotinib, ceritinib (IA), alectinib (IA) or brigatinib 
(IIA) can be recommended. Ceritinib and alectinib have 
shown a significant improvement in median PFS and less 
adverse events than chemotherapy. Brigatinib has shown 
a favorable PFS in a crizotinib-refractory ALK-positive 
phase II trial [84–86].
• Lorlatinib has shown activity in patients who have pro-
gressed on next-generation ALK TKI (ceritinib, alectinib 
or brigatinib) [87] (II,A).
• Ensartinib and entrectinib have also been demonstrated 
activity in previously treated patients in early phase trials 
[88, 89].
• For patients with systemic symptomatic progression to 
ALK TKI, platinum-based chemotherapy remains the 
standard of care (II,A). The combination of atezolizumab 
plus bevacizumab plus chemotherapy has demonstrated 
a significant PFS benefit (III,B) [50].
Brain metastases
• Alectinib, brigatinib and lorlatinib have showngreater 
activity in CNS disease. In the ALEX trial, fewer patients 
treated with alectinib (12%) had CNS progression than 
crizotinib (45%). In the ALTA-1 trial, intracranial RR 
was 78% for brigatinib versus 29% for crizotinib [82].
• For asymptomatic or patients who became asymptomatic 
with steroids, brain-penetrable ALK TKIs may be used 
and local treatments may be deferred (I,B).
ROS‑1 and other rare targetable genetic alterations
• Crizotinib is indicated for the treatment of ROS-1-pos-
itive advanced NSCLC based on the results of a single-
arm trial in 50 patients [90] (III,A).
• Dabrafenib–Trametinib is indicated for the treatment 
of advanced NSCLC  BRAFV600E mutation based on 
results from non-comparative studies in pretreated or 
naïve patients [91, 92] (II,A).
• New investigational drugs have shown activity in 
early clinical trials targeting oncogenic drivers such 
as crizotinib, tepotinib or capmatinib (MET amplified, 
 METe14 mutation), LOXO-292 and BLU-667 (RET), 
entrectinib (NRTK, ROS, ALK fusions), LOXO-101 or 
larotrectinib (NRTK fusions) [93] and ado-trastuzumab 
emtansine (HER2 mutations). However, none of these 
targeted drugs have an official regulatory approval by 
EMA except the orphan drug designation of LOXO-101 
in NTRK fusion tumors.
Oligometastatic NSCLC
The oligometastatic state consists of patients with metasta-
sis limited in number and location. The number of metas-
tases ranges from a single metastatic lesion to a single 
organ with multiple metastases or to multiple lesions in 
multiple organs. The most accepted number of metastatic 
lesions is up to five and, most important, these should 
be suitable to radical treatment by local therapy: surgi-
cal resection, SART or both. The oligometastatic disease 
comprises four different settings [94]:
1. Metastatic lesions limited in number and location at 
diagnosis, all the lesions including the primary tumor 
are suitable to radical therapy.
2. Multiple metastases that are transformed into an oli-
gometastatic disease after systemic treatment due to 
response, and all lesions can be managed with radical 
intent.
3. The primary tumor and most areas of metastatic disease 
remain controlled, but one or a limited number of metas-
tases progress while systemic therapy.
4. Oligorecurrence occurs in patients treated with cura-
tive intent and metachronously present 1–5 metastastic 
lesions suitable to ablative therapy.
• Patients with oligometastatic disease at diagno-
sis should be treated with systemic therapy and 
local consolidative ablative therapy (LAT) to pri-
mary and all metastatic sites. Two phase II studies 
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showed that LAT after systemic therapy increased 
PFS vs no further local treatment [95, 96] (I,A).
• Patients with actionable mutations receiving targeted 
therapies who progress on isolated site can be treated 
with LAT [75, 97] (II,A).
Management and follow‑up
• Smoking cessation counseling is encouraged in any stage 
as it leads to superior treatment outcomes since smoking 
may impact on drugs’ bioavailability (II,A).
• There is not an established consensus regarding the most 
optimal follow-up in patients with NSCLC. However, due 
to the inherent aggressiveness of the disease, a close fol-
low-up is advised.
Follow up in patients after curative treatment:
• NSCLC patients treated with radical intent must be fol-
lowed to identify treatment-related complications, detec-
tion of treatable relapse or occurrence of second primary 
lung cancer (III,A).
• In patients with curative surgery, a close follow-up visit 
including medical history, physical examination and chest 
CT is recommended every 6–12 months for the first 2 years 
and annually thereafter (III,B).
• For patients treated with SART with radical intent, CT 
scans every 6 months for 3 years are recommended and 
annually thereafter (III,B). PET–CT ± biopsy is endorsed 
when recurrence is suspected based on chest CT To dis-
criminate from focal fibrosis (III,B).
• Routine surveillance with blood test, FDG-PET imaging 
or another radiological assessment is not endorsed (II,D).
Follow up in patients with advanced disease:
• Early palliative care is strongly recommended [98] (I,A).
• Evaluation of response is recommended every 6–12 weeks 
after therapy initiation, using the same baseline radio-
graphic method. The frequency of the radiologic assess-
ment can be tailored for patients benefiting long time on 
targeted agents (III,B).
• For patients eligible for successive lines that respond to 
first-line treatment, it is advisable to undergo clinical and/
or radiological evaluation 6 weeks after finishing treatment 
and then every 6–12 weeks to enable second-line therapy 
to commence promptly (III,B).
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